Natera, Inc. $NTRA Shares Bought by Future Fund LLC

Future Fund LLC increased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 39.1% during the 4th quarter, HoldingsChannel reports. The fund owned 13,301 shares of the medical research company’s stock after acquiring an additional 3,741 shares during the quarter. Natera comprises approximately 1.1% of Future Fund LLC’s portfolio, making the stock its 23rd biggest holding. Future Fund LLC’s holdings in Natera were worth $3,047,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Horizon Investments LLC acquired a new position in shares of Natera during the 3rd quarter valued at about $32,000. Flagship Harbor Advisors LLC purchased a new stake in Natera in the 4th quarter valued at about $41,000. Sound Income Strategies LLC raised its holdings in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Natera in the 4th quarter valued at about $62,000. Finally, AXS Investments LLC purchased a new stake in Natera in the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Stock Performance

NTRA stock opened at $223.37 on Friday. The company’s 50 day moving average price is $202.37 and its 200 day moving average price is $215.69. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a market capitalization of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.57.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the prior year, the firm earned ($0.41) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. BTIG Research cut their price target on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $256.60.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 482 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer directly owned 57,496 shares in the company, valued at approximately $12,102,333.04. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 902 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $206.16, for a total transaction of $185,956.32. Following the sale, the chief executive officer owned 149,867 shares in the company, valued at $30,896,580.72. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 41,356 shares of company stock valued at $8,374,584 over the last three months. 5.63% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.